crystal deposits in renal tubules. Our independent metabolite profiling of SGX523 indicates that a major NADPH-independent, late-eluting metabolite (M11) was generated by monkey and human liver S-9, and to a lesser extent by rat S-9, while M11 was absent in dog S-9 incubations.
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INTRODUCTION
There has been much effort over the past several years to develop targeted therapy for oncological indications to improve efficacy and tolerability. One compelling therapeutic target is c-MET, a receptor tyrosine kinase implicated in the control of multiple signal transduction pathways involved in tumor growth and metastasis (Liu et al., 2008) . SGX523 (6-(6-(1-methyl-1H-pyrazol-4-yl)- [1, 2, 4] triazolo [4,3-b] pyridazin-3-ylthio) quinoline) is an orally bioavailable, potent and selective small molecule inhibitor of c-MET and this compound was one of the first selective c-MET inhibitors to be evaluated in patients (Buchanan et al., 2009) . Since the microsomal metabolism profile of SGX523 was similar among rats, dogs, monkeys and humans, IND enabling studies were conducted in rats and dogs (Burley, 2009) . The SGX523 Phase I study was started at a dose of 40 mg in patients. After escalating to doses > 80 mg of SGX523 in patients, acute renal failure was observed as evidenced by increased serum creatinine. The analysis of samples from the discontinued clinical trial revealed a metabolism profile different than that of the preclinical species studied. Subsequent in vivo studies using monkeys demonstrated obstructive nephropathy with intratubular crystal formation, consistent with human data, but the mechanism involved in the toxicity has not been reported (Burley, 2009) . In an effort to better understand this apparent species difference in metabolism and the consequent development of drug induced crystal nephropathy in a species-specific manner, we prepared SGX523 and studied its metabolite profile.
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MATERIAL AND METHODS
Chemicals and Reagents
All chemicals, including allopurinol, oxipurinol, methotrexate, menadione, raloxifene, SKF525-A (proadifen hydrochloride) and H 2 18 O (97 atom % 18 O) was purchased from SigmaAldrich (St. Louis, MO). Male and female pooled liver S-9 fractions prepared from IGS SpagueDawley rats, beagle dogs, cynomolgus monkeys or humans were purchased from XenoTech (Lenexa, KS). Human hepatic cytosol as well as cynomolgus monkey hepatic cytosol and microsomes were purchased from both XenoTech (Lenexa, KS) and Celsis InVitro Technologies (Baltimore, MD).
SGX523 (6-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio) quinoline)
was synthesized by Incyte Corporation (Wilmington, DE) (1-methyl-1H-pyrazol-4-yl) [1, 2, 4] triazolo [4,3-b] pyridazine-3-thiol and 6-bromoquinolin-2(1H)-one (Zaragoza, et al., 2005) , by methods analogous to those described in patent WO This article has not been copyedited and formatted. The final version may differ from this version. 
In Vitro Enzyme Assays
SGX523 was incubated in triplicate at 37˚C in a shaking water bath with liver S-9 fractions prepared from rats (N=400, mixed gender), beagle dogs (N=10, mixed gender), cynomolgus monkeys (N=10, mixed gender) or humans (N=50, mixed gender). Incubations included liver S-9 fraction (1 mg protein/mL), potassium phosphate buffer (50 mM, pH 7.4) with or without NADPH (1.0 mM), and SGX523 (5 µM) which was used to initiate the reaction. In a second experiment, SGX523 was incubated in triplicate at 37˚C in a shaking water bath with either hepatic microsomes, S-9, or cytosol (1 mg protein/mL) prepared from cynomolgus monkeys (N=10, mixed gender for each preparation) and potassium phosphate buffer (50 mM, pH 7.4) with or without NADPH (1.0 mM) at the final concentrations indicated. For these incubations, SGX523 (5 µM) was used to initiate the reaction. In a third experiment, the effects of various molybdenum hydroxylase inhibitors on the formation of M11 in monkey and human liver cytosol were examined. These chemical inhibitor studies were carried out at 37˚C in a shaking water bath and included monkey or human liver cytosol (1 mg/mL), potassium phosphate buffer (50 mM, pH 7.4) and SGX523 (5 µM) with or without the chemical inhibitor. The chemical inhibitors allopurinol (Massey et al., 1970) , oxipurinol (Massey et al., 1970) and methotrexate (Lewis et al., 1984) were used to selectively inhibit cytosolic XO, while menadione (Johns, 1967) , raloxifene (Obach, 2004) , and SKF525-A (Robertson and Bland, 1993) were used to This article has not been copyedited and formatted. The final version may differ from this version. 
Equilibrium Solubility Determinations
The solubilities of SGX523 and M11 were determined in 0.1 N HCl (pH 1.0), water (pH 6.8), potassium phosphate buffer (0.1 M, pH 7.4) and in blank control monkey urine (pH 8.4).
Compound was accurately weighed and 1 mL of the appropriate matrix was added. Vials were capped and incubated at 37˚C overnight. Samples were then centrifuged and filtered using a 0.45 μm filter, and the concentrations of SGX523 or M11 in the filtrate were determined by the quantitative LC/MS/MS analysis method described below. For both SGX523 and M11, experiments were conducted to determine the nonspecific binding to the filter. Experiments showed that SGX523 was not retained on the filter. For M11, 20 to 40% of the compound was retained on the filter in various matrices, therefore filtrate concentrations were corrected accordingly.
Analytical Methods for Quantitative Analysis
The concentration of M11 in samples generated from in vitro studies was determined using Genesis AQ HPLC column (2.0 x 150 mm, 4μm, Grace/Vydac, Deerfield, IL, USA) with a gradient elution scheme consisting of mobile phase A: 5 mM ammonium formate in water (pH 3.2) and mobile phase B: acetonitrile. Mobile phase B was increased linearly from 25% to 95% over 8 minutes using a flow rate of 600 µL/min. The M11 metabolite (m/z 376.0) peak was integrated from extracted ion chromatograms, and the amounts were determined from a standard curve based on peak area. Calibration curves generally were linear from 0.020 µM -1.0 µM.
The concentration of SGX523 and M11 in plasma samples and solubility studies were determined by another LC/MS/MS method. The monkey plasma samples were subjected to protein precipitation with four volumes of 90% acetonitrile in methanol, centrifuged, and the resulting supernatants were dried down and reconstituted with a 25% acetonitrile in water and then subjected to LC/MS/MS analysis. Plasma supernatants and filtrates from solubility studies were injected onto a Phenomenex Synergi 4µ polar-RP 50x2 mm 80A coupled to Sciex API 3000 triple quadruple mass spectrometer and separation was achieved using a gradient elution consisting of mobile phase A: 0.1% formic acid in water and mobile phase B: 0.1% formic acid in acetonitrile. Mobile phase B was increased linearly from 5% to 65% over 5 minutes using a flow rate of 300 µL/min. The ionization was optimized using ESI(+) and detection was via 
Analytical Methods for Metabolite Profiling
For metabolite profiling, plasma samples from individual monkeys were pooled according to the Hamilton pooling method (Hamilton et al., 1981) , while urine samples were analyzed individually. Aliquots of plasma and urine samples were precipitated with one or two volumes of acetonitrile:methanol:DMSO (1:1:1, v/v), placed in a sonicating water bath for 10 minutes, vortex mixed, and then centrifuged. The resulting supernatants were then subjected to direct LC/MS/MS analysis. SGX523 metabolism samples from both the in vitro S-9 incubations and the in vivo studies were analyzed using electrospray ionization LC/MS/MS with an Applied
Biosystems 4000 Q TRAP hybrid triple quadrupole/linear ion trap mass spectrometer (Applied Biosystems, Foster City, CA) operated in positive ionization mode. SGX523 and its metabolites were separated on an ACE C18 column (4.6 x 150 mm, 3μm, Advanced Chromatography This article has not been copyedited and formatted. The final version may differ from this version. was detected at trace levels in all but the dog liver S-9 incubations. The abundance of these metabolites was decreased by the pan-cytochrome P450 inhibitor, aminobenzotriazole (data not shown). In contrast, a major late-eluting and therefore presumed to be less polar metabolite formation was inhibited by SKF525-A in human cytosol (62% of control). It should be noted that inhibition of molybdenum hydroxylases is less understood than is the case with cytochrome P450s, and the same AO inhibitor can exhibit different inhibitory potentials among species, and for different marker substrates (Sahi et al., 2008) . Together these data suggested that AO and not XO is the enzyme responsible for the formation of the M11 metabolite in the monkey and human.
Water is the Source of Oxygen Atom in M11
LC/MS analysis of SGX523 incubations with cynomolgus monkey liver S-9 fraction in the presence of H 2 18 O indicate that 100% of the oxygen incorporated into M11 was sourced from the This article has not been copyedited and formatted. The final version may differ from this version. 
M11 is a Major Metabolite Detected in Monkey Plasma and Urine
LC/MS/MS analysis of plasma and urine from cynomolgus monkeys dosed orally with
SGX523 shows that M11 is a major metabolite in plasma and urine for this species (Figure 4 ). were detected, albeit to a lesser extent. Estimation of the quantities of metabolites is based solely on full scan mass spectral response, which is highly analyte specific and considered semiquantitative in the absence of authentic standards. Table 2 shows that after IV dosing in monkeys, SGX523 exhibited low clearance (0.22 L/h/kg), and a moderate volume of distribution (0.6 L/kg). The half-life value for SGX523 was 4.1 h.
In addition to M11, M5 (N-desmethyl
Pharmacokinetics and Urinary Excretion
Approximately 0.2% of the administered IV dose was excreted in monkey urine as intact SGX523. After oral dosing, the average plasma Cmax value was 4.8 μM, and the oral bioavailability was moderate (39%). In urine samples solubilized with a mixture of organic solvents and DMSO, the concentration of M11 (29.2 μM) was ~ 70-fold greater than that of parent compound (0.4 μM) following a single oral dose of SGX523.
M11 is Less Soluble than SGX523
SGX523 exhibits marked pH-dependent solubility, with a solubility value that ranged from 2734 μg/mL in acid at pH 1.0 to only 4 μg/mL at pH 7.4 (Table 3 ). In addition, SGX523 was soluble in monkey urine at a concentration limit of 13 μg/mL. The intrinsic solubility of M11 was remarkably lower than that of the parent compound, with solubility values in water (pH 6.8),
buffer (pH 7.4), acid (pH 1.0), and monkey urine (pH 8.4) of only 0.13, 0.10, 0.25 and 0.37 μg/mL, respectively. Therefore in urine, the solubility value for M11 (0.37 μg/mL) was only 3%
of that of SGX523 (13 μg/mL). Moreover, this metabolite did not exhibit the striking pHdependent solubility noted for intact SGX523, since the solubility range was only ~ 3-fold between acidic and neutral conditions for M11.
DISCUSSION
During drug discovery, the metabolism of new drug candidates is typically evaluated using hepatic microsomes because the vast majority of drugs are cleared via cytochrome P450s. This P450 focused evaluation can lead researchers to underestimate the contribution from non-CYP enzymes such as cytosolic aldehyde oxidase (AO). Understanding the metabolic pathways and enzymes responsible for metabolite formation across species can improve predictions for pharmacokinetic, pharmacological and toxicological extrapolations to humans. Ultimately, metabolite profiling data should be incorporated into the decision to select the most clinically relevant species for nonclinical safety assessment, thereby potentially avoiding those situations in which metabolites require further independent toxicological evaluations as outlined in the FDA metabolite safety guidance ("MIST"). This is especially important to consider for AO since activity in humans is relatively high compared to the commonly used preclinical safety species of rats and dogs (Smith and Obach, 2009 ).
The current investigation provides evidence that SGX523 is metabolized by AO, in a speciesspecific manner, to a markedly less-soluble metabolite, 2-quinolinone-SGX523 (M11). We propose that M11 may have precipitated in the renal tubule leading to crystal nephropathy and obstructive renal failure in patients. Acute renal failure attributed to precipitation of drug has been reported for a number of pharmaceuticals including acyclovir, sulfonamide, methotrexate, and indinavir (Perazella, 1999) . In such cases, nephrotoxicity occurs when drug related material exceeds its solubility limit and precipitates in the tubular lumen of the nephron. Such a clinical finding was not anticipated for SGX523 based on initial preclinical studies conducted in rats and Our in vitro studies using liver S-9 fractions from rats, monkeys, dogs and humans showed that SGX523 underwent species-dependent metabolism. A late-eluting metabolite (M11, 2-quinolinone-SGX523) was generated by monkey and human liver S-9, and to a lesser extent by rat liver S-9, while this metabolite was completely absent in dog liver S-9 incubations. While additional NADPH-dependent polar metabolites have been detected, these metabolites were not characterized because a marked species difference was not evident. It is important to note that this species-specific pattern of metabolism, obvious when using S-9 incubations, would not be apparent if microsomes were used. Since M11 was produced by NADPH-independent cytosolic enzymes, and water supplied the oxygen atom incorporated into the substrate, the subsequent in vitro experiments focused on molybdenum hydroxylases. There are two major molybdenum hydroxylases that participate in the metabolism of drugs, aldehyde oxidase (AO) and xanthine oxidase (XO). In vitro experiments using monkey and human liver cytosol with selective chemical inhibitors of these enzymes demonstrated that AO, and not XO, metabolized SGX523 to M11. This enzyme is implicated by the fact that the formation of M11 was inhibited significantly by two (menadione and raloxifene) of the three known selective inhibitors of AO studied in monkey cytosol, and all three AO inhibitors in human cytosol (menadione, raloxifene and SKF525A). In contrast, none of the selective inhibitors of XO inhibited the formation of M11 in monkey or human cytosol.
This article has not been copyedited and formatted. The final version may differ from this version. Importantly, the species differences noted for the levels of this AO-mediated metabolite of SGX523 generated during in vitro S-9 incubations are consistent with the reported speciesdependent differences described for hepatic AO expression. For most N-heterocycles that are substrates for AO, the monkey and human exhibit the highest activity of hepatic AO, with lower activities reported for rat, and little to no AO activity in beagle dogs (Austin et al., 2001 , Beedham et al., 1987 , Kawashima et al. 1999 , Sugihara et al., 2000 . The extent of the species differences reported for AO activity is substrate-dependent, because the size of the active and binding sites of this enzyme varies among species (Beedham et al., 1990; Beedham et al.,1995 ).
An example of another quinoline containing small molecule that was metabolized in a speciesspecific manner by AO is SB-277011 (Austin et al., 2001 ). The high clearance of SB-277011 in monkeys, and not in rats and dogs, was attributed to a major metabolic pathway via oxidation on the quinoline ring by AO. These authors also noted that not all N-heterocylic containing compounds from the same series as SB-277011 were substrates for AO, suggesting it is not always possible to predict metabolism via AO within a chemical series. Despite the remarkable differences noted, often AO is not rigorously examined or considered as there is no known case of a drug exclusively metabolized by AO, and few drugs are predominantly metabolized by AO.
Additional information supporting the generation of M11 by AO comes from the chemical structure of SGX523 and what is known in terms of affinity of AO for substrates. Aldehyde oxidase is a molybdozyme that can oxidize a number of nitrogen-containing heterocyles including quinolines (Kitamura et al., 2006) . A main characteristic of this cytosolic enzyme is that it catalyzes nucleophilic oxidation at an electron deficient carbon atom usually adjacent to the nitrogen atom of the heterocycle. This is unlike cytochrome P450 which prefers to oxidize This article has not been copyedited and formatted. The final version may differ from this version. carbon atoms with high electron density. Therefore, it can be inferred that AO is the more likely enzyme to produce the 2-quinolinone metabolite of SGX523. The M11 metabolite exhibits markedly lower solubility than parent compound under acid, neutral and basic conditions, with solubility values well below 1 µg/mL. Specifically, the solubility of M11 (0.37 μg/mL) in urine was only 3% of that of parent SGX523 (13 μg/mL). Moreover, this metabolite did not exhibit the striking pH-dependent solubility noted for intact SGX523, since the solubility value between acidic and neutral conditions for the metabolite only differed ~ 3-fold vs. 684-fold for parent compound. The dramatic difference in aqueous solubility and pH-dependent solubility between SGX523 and M11 is due to the fact that the basic nitrogen of the quinoline functional group is converted to the neutral lactam species in M11. Thus, the resulting change in pKa would adversely affect ionization and solubility of the 2-quinolinone metabolite at physiological conditions. AO-generated lactam functional groups are inherently less water soluble than their precursors. For example, methotrexate is metabolized via AO to the less soluble 7-hydroxymethotrexate metabolite, as the aqueous solubility of this metabolite (1.55 mg/mL) at pH 7 is ~20% of that of parent (8.90 mg/mL) solubility (Jacobs et al., 1976) . However, the effects of the lactam on aqueous solubility of the metabolite as a whole may be mitigated by other polar or ionizable functionalities. Therefore, poor water solubility is not always a hallmark characteristic of lactam metabolites.
SGX523 exhibited low clearance (~10% HBF) in cynomolgus monkeys after IV dosing, and moderate oral bioavailability (~39%). While metabolite profiling of plasma showed that intact parent compound was the major moiety detected, this compound was significantly metabolized via AO-mediated pathways as evidenced by the presence of both the M11 metabolite, and its N- demethyl analog (M8). SGX523 was presumably cleared via the hepatic route, since less that 1% of the administered IV dose was excreted in urine as intact SGX523. In urine solubilized with a mixture of organic solvents and DMSO, M11 was the major moiety detected, and this metabolite was detected at levels ~70-fold greater than that of parent compound. The concentration of the M11 metabolite measured in monkey urine after an oral dose was 29.2 μM, ~37-fold above the in vitro solubility limit in drug-free monkey urine at body temperature (0.29µg/mL = 0.8 μM). It is sometimes difficult to predict compound precipitation by simply comparing compound solubility in drug-free urine to the concentration measured in urine samples from subjects after oral dosing, presumably because of supersaturation in the kidney (Merschman et al., 2005) . In addition, the kidney may have contributed to the AO-mediated metabolism of SGX523. While the tissue distribution of AO in the cynomolgus monkeys has not been reported, the proximal, distal and collecting tubules of the human kidney, but not the glomerulus, have been shown to express AO (Moriwaki et al., 2001 ).
In summary, a predominant metabolic pathway of SGX523 in monkeys has been identified both in vitro and in vivo as oxidation of the quinoline ring ( Figure 5 ). The major metabolite has been confirmed as 2-quinolinone SGX523 (M11), and it was formed in vitro in a species-specific manner. This metabolite demonstrated markedly lower solubility than that of parent compound and in particular did not show the enhanced solubility at acidic conditions that the parent compound did. In addition, the extent of the urinary excretion of M11 was significantly greater than that of SGX523. Collectively, these data suggest that this 2-quinolinone metabolite is likely involved in the observed obstructive nephropathy in humans and also provides an explanation for 
